CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP) announced participation in two upcoming virtual investor conferences. The Credit Suisse 30th Annual Healthcare Conference is scheduled for November 8, 2021, at 1:00 p.m. ET, followed by the Barclays Gene Editing & Gene Therapy Summit on November 15, 2021, at 10:00 a.m. ET. Live webcasts will be available on the company's website, with replays archived for 14 days post-event. CRISPR Therapeutics specializes in gene editing using its CRISPR/Cas9 platform, addressing serious diseases through innovative therapeutics.

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in November:

Credit Suisse 30th Annual Healthcare Conference
Date: Monday, November 8, 2021
Time: 1:00 p.m. ET.

Barclays Gene Editing & Gene Therapy Summit
Date: Monday, November 15, 2021
Time: 10:00 a.m. ET

A live webcast of the events will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcasts will be archived on the Company's website for 14 days following each presentation.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com

Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com

FAQ

What are the dates for CRSP's upcoming investor conferences?

CRISPR Therapeutics will participate in the Credit Suisse 30th Annual Healthcare Conference on November 8, 2021, and the Barclays Gene Editing & Gene Therapy Summit on November 15, 2021.

At what time will CRSP present at the Credit Suisse conference?

CRISPR Therapeutics is scheduled to present at the Credit Suisse 30th Annual Healthcare Conference at 1:00 p.m. ET.

Where can I watch the CRSP investor conference webcasts?

Live webcasts for CRISPR Therapeutics' investor conferences will be available on the 'Events & Presentations' page on their website.

How long will the webcasts from CRSP's conferences be available?

The replays of the webcasts from CRISPR Therapeutics' conferences will be archived for 14 days following each presentation.

What is CRSP known for in the biopharmaceutical industry?

CRISPR Therapeutics is known for developing transformative gene-based medicines using its proprietary CRISPR/Cas9 gene editing technology.